<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Interleukin-17 (IL-17) is active in a variety of brain injuries, including <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of this study was to test the hypothesis that IL-17 potentiates neuronal injury after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Increased expression of IL-17 and IL-17 receptor (IL-17R) in serum and cortex was evaluated by ELISA, RT-PCR and immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>In the in vitro model of oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation (OGD), IL-17 showed a dose-dependent effect in promoting neuronal injury through IL-17-IL-17R combination which can be blocked by IL-17R/Fc chimera </plain></SENT>
<SENT sid="4" pm="."><plain>Our results demonstrated the up-regulation of IL-17 and IL-17R following permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and suggested that they contributed to <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome </plain></SENT>
</text></document>